Advertisement


Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Immunotherapy Update

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.



Related Videos

Solid Tumors
Immunotherapy

Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results

Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor ...

Kidney Cancer
Immunotherapy

Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging...

Lung Cancer
Immunotherapy

Roy S. Herbst, MD, PhD, on Personalized Immunotherapy for Lung Cancer: Expert Perspective

Roy S. Herbst, MD, PhD, of the Yale School of Medicine, summarizes a session that included discussion of the mechanisms of immunotherapies, biomarkers for activity of these agents,...

Solid Tumors
Immunotherapy

Jeffrey M. Lemons, MD, on Solid Tumors: Safety Data on SBRT and Immunotherapy

Jeffrey M. Lemons, MD, of the University of Chicago, discusses early safety and efficacy findings from a small study on pembrolizumab and multiorgan-site ablative stereotactic body...

Issues in Oncology
Immunotherapy

Aaron Goodman, MD, on Immune Checkpoint Blockade: Clinical Implications

Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification an...

Advertisement

Advertisement



;
Advertisement